Drug Trial Radar · NCT07652294
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
645
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
Mar 2, 2029
Study completion Jan 3, 2030
Sponsor
- Lead sponsor
- Spyre Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study).
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative
Interventions
SPY001Drug
Experimental
SPY002Drug
Experimental
SPY003Drug
Experimental
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experienced an adverse eventTime frame: Week 96
Locations
100 sites in 24 countries. Site status is shown where the registry gives one.
Site 023
La Jolla, California
Site 012
Lancaster, California
Site 007
Kissimmee, Florida
Site 035
Marrero, Louisiana
Site 028
Rochester, Minnesota
Site 025
Providence, Rhode Island
Study Site 002
San Antonio, Texas
Site 008
Southlake, Texas
Site 019
Tacoma, Washington
Site 102
Lujan de Cuyo, Mendoza Province, Argentina
Site 103
Rosario, Santa Fe Province, Argentina
Site 208
Concord, New South Wales, Australia
Site 206
South Brisbane, Queensland, Australia
Site 461
Salzburg, Austria
Site 463
Linz, Upper Austria, Austria
Site 473
Leuven, Flemish Brabant, Belgium
Site 471
Ghent, Oost-Vlaanderen, Belgium
Site 126
Passo Fundo, Rio Grande Sul, Brazil
Site 128
Santo André, São Paulo, Brazil
Site 153
Osorno, Los Lagos Region, Chile
Site 152
Santiago, Santiago Metropolitan, Chile
Site 531
Brno, Czechia
Site 584
Kutaisi, Georgia
Site 589
Marneuli, Georgia
Site 581
Tbilisi, Georgia
Site 588
Tbilisi, Georgia
Site 583
Tbilisi, Georgia
Site 586
Tbilisi, Georgia
Site 582
Tbilisi, Georgia
Site 587
Tbilisi, Georgia
Site 603
Ulm, Germany
Site 634
Athens, Greece
Site 654
Békéscsaba, Hungary
Site 651
Budapest, Hungary
Site 652
Székesfehérvár, Hungary
Site 673
Legnano, Milan, Italy
Site 672
Negrar, Verona, Italy
Site 424
Amman, Jordan
Site 421
Amman, Jordan
Site 422
Irbid, Jordan
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.